These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 9731234)
1. Fine structural and functional consequences of deglycosylation of the platelet adhesion receptor GPIb-IX (CD 42b). Moshfegh K; Lengweiler S; Häner M; Aebi U; Steiner B; Beer JH Biochem Biophys Res Commun; 1998 Aug; 249(3):903-9. PubMed ID: 9731234 [TBL] [Abstract][Full Text] [Related]
2. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib. Girma JP; Takahashi Y; Yoshioka A; Diaz J; Meyer D Thromb Haemost; 1990 Oct; 64(2):326-32. PubMed ID: 1702906 [TBL] [Abstract][Full Text] [Related]
3. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX. Yuan Y; Zhang W; Yan R; Liao Y; Zhao L; Ruan C; Du X; Dai K Circ Res; 2009 Dec; 105(12):1177-85. PubMed ID: 19875727 [TBL] [Abstract][Full Text] [Related]
4. Differential aspects of the glycoprotein Ib-von Willebrand factor axis in human and pig species. Zurbano MJ; Escolar G; Heras M; Ordinas A; Castillo R Haematologica; 2000 May; 85(5):514-9. PubMed ID: 10800169 [TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of jararaca GPIb-BP, a snake venom antagonist specific to platelet glycoprotein Ib. Fujimura Y; Ikeda Y; Miura S; Yoshida E; Shima H; Nishida S; Suzuki M; Titani K; Taniuchi Y; Kawasaki T Thromb Haemost; 1995 Aug; 74(2):743-50. PubMed ID: 8585016 [TBL] [Abstract][Full Text] [Related]
6. Inhibition assay for the binding of biotinylated von Willebrand factor to platelet-bound microtiter wells in the presence of ristocetin or botrocetin. Miura S; Nishida S; Makita K; Sakurai Y; Shimoyama T; Sugimoto M; Yoshioka A; Ishii K; Kito M; Kobayashi T; Fujimura Y Anal Biochem; 1996 May; 236(2):215-20. PubMed ID: 8660497 [TBL] [Abstract][Full Text] [Related]
7. Infusible platelet membranes retain partial functionality of the platelet GPIb/IX/V receptor complex. Graham SS; Gonchoroff NJ; Miller JL Am J Clin Pathol; 2001 Jan; 115(1):144-7. PubMed ID: 11190800 [TBL] [Abstract][Full Text] [Related]
8. Functional expression of single chain glycoprotein Ib alpha on the surface of COS cells and BHK cells. Petersen EJ; Posthumus E; Sixma JJ Thromb Haemost; 1996 Nov; 76(5):768-73. PubMed ID: 8950788 [TBL] [Abstract][Full Text] [Related]
9. Mutant botrocetin-2 inhibits von Willebrand factor-induced platelet agglutination. Matsui T; Hori A; Hamako J; Matsushita F; Ozeki Y; Sakurai Y; Hayakawa M; Matsumoto M; Fujimura Y J Thromb Haemost; 2017 Mar; 15(3):538-548. PubMed ID: 28071872 [TBL] [Abstract][Full Text] [Related]
10. Crotalin, a vWF and GP Ib cleaving metalloproteinase from venom of Crotalus atrox. Wu WB; Peng HC; Huang TF Thromb Haemost; 2001 Dec; 86(6):1501-11. PubMed ID: 11776320 [TBL] [Abstract][Full Text] [Related]
11. A novel monoclonal antibody against the extracellular domain of GPIbbeta modulates vWF mediated platelet adhesion. Perrault C; Moog S; Rubinstein E; Santer M; Baas MJ; de la Salle C; Ravanat C; Dambach J; Freund M; Santoso S; Cazenave JP; Lanza F Thromb Haemost; 2001 Nov; 86(5):1238-48. PubMed ID: 11816713 [TBL] [Abstract][Full Text] [Related]
12. von Willebrand factor mediates platelet spreading through glycoprotein Ib and alpha(IIb)beta3 in the presence of botrocetin and ristocetin, respectively. McCarty OJ; Calaminus SD; Berndt MC; Machesky LM; Watson SP J Thromb Haemost; 2006 Jun; 4(6):1367-78. PubMed ID: 16706984 [TBL] [Abstract][Full Text] [Related]
13. Evidence from limited proteolysis of a ristocetin-induced conformational change in human von Willebrand factor that promotes its binding to platelet glycoprotein Ib-IX-V. Kang M; Wilson L; Kermode JC Blood Cells Mol Dis; 2008; 40(3):433-43. PubMed ID: 17977030 [TBL] [Abstract][Full Text] [Related]
14. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease. Tout H; Obert B; Houllier A; Fressinaud E; Rothschild C; Meyer D; Girma JP Thromb Haemost; 2000 Feb; 83(2):274-81. PubMed ID: 10739386 [TBL] [Abstract][Full Text] [Related]
15. Characterization of murine anti-glycoprotein Ib monoclonal antibodies that differentiate between shear-induced and ristocetin/botrocetin-induced glycoprotein Ib-von Willebrand factor interaction. Cauwenberghs N; Ajzenberg N; Vauterin S; Hoylaerts MF; Declerck PJ; Baruch D; Deckmyn H Haemostasis; 2000; 30(3):139-48. PubMed ID: 11014964 [TBL] [Abstract][Full Text] [Related]
16. The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Fukuda K; Doggett T; Laurenzi IJ; Liddington RC; Diacovo TG Nat Struct Mol Biol; 2005 Feb; 12(2):152-9. PubMed ID: 15665869 [TBL] [Abstract][Full Text] [Related]
18. A template-assembled synthetic protein surface mimetic of the von Willebrand factor A1 domain inhibits botrocetin-induced platelet aggregation. Hauert J; Fernandez-Carneado J; Michielin O; Mathieu S; Grell D; Schapira M; Spertini O; Mutter M; Tuchscherer G; Kovacsovics T Chembiochem; 2004 Jun; 5(6):856-64. PubMed ID: 15174170 [TBL] [Abstract][Full Text] [Related]
19. How does agkicetin-C bind on platelet glycoprotein Ibalpha and achieve its platelet effects? Xu G; Ulrichts H; Vauterin S; De Meyer SF; Deckmyn H; Teng M; Niu L Toxicon; 2005 Apr; 45(5):561-70. PubMed ID: 15777951 [TBL] [Abstract][Full Text] [Related]